Press Releases

Vancouver, British Columbia--(Newsfile Corp. - April 27, 2026) - InMed Pharmaceuticals Inc. (NASDAQ:INM) ("InMed" or the "Company"), a pharmaceutical company focused on developing a pipeline of proprietary small molecule drug candidates for diseases with high unmet medical needs, today announces that it has entered into amending agreements in respect of preferred investment options previously entered into with each of Sabby Volatility Warrant Master Fund, Ltd. ("Sabby") and certain affiliates of H.C. Wainwright & Co., LLC (the "Wainwright Parties").As previously reported: pursuant to the terms of the preferred investment options dated October 26, 2023 and June 26, 2025 (together, the "Sabby

CARY, N.C., April 27, 2026 (GLOBE NEWSWIRE) -- Heron Therapeutics, Inc. (NASDAQ:HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced that the Company will host a conference call and live webcast on Monday, May 11, 2026, at 8:30 a.m. ET to report first quarter 2026 financial results and discuss recent business highlights. The conference call can be accessed by phone by utilizing the following registration link which will provide participants with dial-in details. To avoid delays, we encourage participants to dial into the conference call fifteen minutes ahead of the scheduled start time. The conference call will also be available via webcast under the

MILWAUKEE, April 27, 2026 /PRNewswire/ -- Louis Pinkham, Chief Executive Officer of Regal Rexnord Corporation (NYSE:RRX), announced that the Board of Directors, at its regular quarterly meeting held on April 27, 2026, declared a dividend of $0.35 per share. The dividend is payable on July 14, 2026, to shareholders of record at the close of business on June 30, 2026. The company has paid a dividend every quarter since January 1961. About Regal RexnordRegal Rexnord's 30,000 associates around the world help create a better tomorrow by providing sustainable solutions that power, transmit and control motion. The Company's electric motors and air moving subsystems provide the power to create motio

Veradermics, Incorporated ("Veradermics") (NYSE:MANE), a dermatologist-founded, late clinical-stage biopharmaceutical company focused on developing innovative therapeutics for pattern hair loss, today announced that it has launched a proposed public offering of 3,350,000 shares of common stock (and, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock) pursuant to a registration statement filed on Form S-1 with the Securities and Exchange Commission ("SEC"). All of the shares and pre-funded warrants are being offered by Veradermics. In addition, the underwriters are expected to have a 30-day option to purchase up to an additional 502,500 s

BBB Foods Inc. (NYSE:TBBB) ("Tiendas 3B" or "the Company") will report its first quarter 2026 earnings on May 6, 2026, after market close. You are invited to join our quarterly conference call, which will be webcast on May 7, 2026, at 12:00 p.m. ET. Anthony Hatoum, Chairman and CEO, and Eduardo Pizzuto, CFO, will host the call and take questions on the results. Event: Tiendas 3B First Quarter 2026 Earnings Conference Call When: May 7, 2026, 12:00 p.m. ET Webinar /Dial In #: To join the webinar: https://zoom.us/webinar/register/WN_gw598N0ZSMeMhTncXb-3LA To join via telephone: Dial one of the domestic or international numbers listed below. Enter the webinar ID (962 4278 7223)

In vitro data demonstrated self-complementary AAV9 (scAAV9) enabled ~30-fold higher MeCP2 protein expression compared to single-stranded AAV9 (ssAAV9), supporting the ability to effectively deliver TSHA-102 to the CNS by lumbar IT administration MiniMeCP2 is functionally comparable to full-length MeCP2 across molecular and biochemical functions, with both proteins exhibiting comparable, stable expression in neuronal cells Data further validate the selection of scAAV9 and miniMeCP2 in the TSHA-102 construct and provide translational support for the Part A REVEAL Phase 1/2 clinical data in patients with Rett syndrome DALLAS, April 27, 2026 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (

NEW YORK, April 27, 2026 (GLOBE NEWSWIRE) -- Lexeo Therapeutics, Inc. (NASDAQ:LXEO), a clinical stage genetic medicine company dedicated to pioneering novel treatments for cardiovascular diseases, announced today that new data supporting its cardiac gene therapy programs and optimized AAV manufacturing approach will be presented at the 29th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT) taking place May 11-15, 2026 in Boston, MA. "We're excited to return to ASGCT with a broad and compelling set of presentations that highlight the depth of Lexeo's science and continued progress across our pipeline, from encouraging cardiac and neurologic data in Friedreich ataxia (FA

PALSONIFY is the first once-daily, oral therapy approved to treat acromegaly in the European Union Approval based on strength of data from two pivotal Phase 3 studies studying PALSONIFY in both medical naïve and previously treated patients with acromegaly Crinetics' first regulatory approval outside of the U.S., with first launch planned for Germany and Austria SAN DIEGO, April 27, 2026 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) today announced that the European Commission (EC) has approved PALSONIFY® (paltusotine), the first once-daily, oral, selectively-targeted somatostatin receptor type 2 nonpeptide agonist, for the treatment of adult patients with acromegaly

Features company's patented SimpliSqueeze® valve for ready-to-dispense convenience, focused on reducing mess and drips AptarGroup, Inc. (NYSE:ATR), a global leader in drug delivery, dosing and protection technologies, and consumer product dispensing, today announced it has launched a new line of inverted lidless dispensing closures for the beauty and personal care markets. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260427887104/en/Aptar's Inverted Lidless Dispensing Closures Aptar's inverted lidless closures help eliminate the need for separate lids while allowing for an inverted, ready-to-dispense packaging format that he

DAYTONA BEACH, Fla., April 27, 2026 (GLOBE NEWSWIRE) -- Brown & Brown, Inc. (NYSE:BRO) (the "Company") announced its unaudited financial results for the first quarter of 2026. For the first quarter ended March 31, 2026, the Company achieved: Total revenues of $1.9 billion, increasing $497 million, or 35.4%, compared to the first quarter of the prior year, with flat Organic Revenue and Organic Revenue with Contingents increasing 2.2%.Income before income taxes of $533 million, increasing 24.8%, with Income Before Income Taxes Margin of 28.0%, compared to 30.4% in the first quarter of the prior year.EBITDAC - Adjusted of $731 million, increasing 36.6%, with EBITDAC Margin - Adjusted of 38.

Airline also introduces up to $250,000 'We Serve Together' grant for Employees and nonprofits they serveDALLAS, April 27, 2026 /PRNewswire/ -- Southwest Airlines Co. (NYSE:LUV) celebrates the 250th anniversary of the nation's founding with the introduction of Independence One, a special new livery from the airline that is known for democratizing the skies. Independence One will join two additional Southwest® America-themed planes—Freedom One, which has been in the fleet since 2021, and Liberty One, a second newly-introduced aircraft painted in an American flag theme. "With our new Independence One and Liberty One aircraft, we honor this important milestone in our

HCA Healthcare (NYSE:HCA) today announced that Cynthia Cifuentes-Finkel has been named senior vice president of marketing and corporate affairs, effective June 8, 2026. She will report to Mike McAlevey, executive vice president, chief legal and administrative officer, and will lead enterprise marketing, corporate communications, and stakeholder engagement in support of HCA Healthcare's enterprise growth priorities. "Cynthia is a strategic and accomplished leader with deep experience building trusted brands, strengthening reputation and aligning communications with organizational strategic imperatives," said McAlevey. "She brings a strong track record of leading high-performing teams, navi

Archer Aviation Inc. (NYSE:ACHR) will report its first quarter 2026 operating update and financial results after market close on Monday, May 11, 2026. The company will host a live webcast to discuss its results at 2:00 p.m. Pacific Time. The live webcast and replay will be available at investors.archer.com.To listen to the conference call, dial 1 833-461-5787 (domestic) or +1 585-542-9983 (international) and enter the access code 641143600. Archer will also utilize Say Technologies' Q&A Platform to allow shareholders to submit and vote on questions by visiting https://app.saytechnologies.com/archer-aviation-2026-q1. About Archer Archer is designing and developing the technologies an

ACHESON, Alberta, April 27, 2026 (GLOBE NEWSWIRE) -- North American Construction Group Ltd. ("NACG" or "the Company") (TSX:NOA, NYSE:NOA) announced today that it will release its financial results for the first quarter ended March 31, 2026 on Wednesday, May 13, 2026 after markets close. Following the release of its financial results, NACG will hold a conference call and webcast on Thursday, May 14, 2026, at 7:00 a.m. Mountain Time (9:00 a.m. Eastern Time). The call can be accessed by dialing:Toll free: 1-800-717-1738Conference ID:96416 A replay will be available through June 12, 2026, by dialing:Toll Free: 1-888-660-6264Conference ID: 96416Playback Passcode: 96416 A slide deck for the w

PHILADELPHIA, April 27, 2026 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (NASDAQ:CABA), a late-stage clinical biotechnology company focused on developing and launching targeted cell therapies designed specifically for patients with autoimmune diseases, today announced multiple upcoming presentations including manufacturing, translational and clinical data on rese-cel (resecabtagene autoleucel) at the American Society of Gene & Cell Therapy (ASGCT) 2026 Annual Meeting, being held from May 11-15, 2026, in Boston, MA. The presentations will feature clinical and translational data from the lowest dose cohort of rese-cel without preconditioning in RESET-PV® (pemphigus vulgaris), and initial transl

BOULDER, Colo., April 27, 2026 (GLOBE NEWSWIRE) -- Auddia Inc. (NASDAQ:AUUD) (NASDAQ:AUUDW) ("Auddia" or the "Company"), a technology company that has built a proprietary AI platform for audio identification and classification to reinvent how consumers engage with audio, today announced the closing of its previously announced best efforts public offering of an aggregate of 5,084,743 shares of its common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to 5,084,743 shares of common stock (the "Warrants"), at a combined public offering price of $2.36 per share (or per common stock equivalent in lieu thereof) and accompanying Warrant. The Warrants have an exerci

Tidewater Inc. (NYSE:TDW) ("Tidewater" or the "Company") announced today that it will release financial results for the three months ending March 31, 2026, on Monday, May 4, 2026 after market close. An earnings conference call has been scheduled for Tuesday, May 5, 2026, at 8:00 a.m. Central Time, during which President and Chief Executive Officer Quintin Kneen will discuss results for the three months ending March 31, 2026. Investors and interested parties may listen to the earnings conference call via telephone by calling +1.800.715.9871 if calling from the U.S. or Canada (+1.647.932.3411 if calling from outside the U.S.) and provide Conference ID: 8745688 prior to the scheduled start t

WAYNE, Pa., April 27, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ:ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that it will provide the full results from its Phase 1a single and multiple ascending dose trial of its anti-TSLP/IL-4R bispecific antibody ATI-052 and the results of its lead indication selection process for its ITK/JAK3 Inhibitor ATI-2138 before the opening of the financial markets tomorrow, April 28, 2026. Aclaris will host a webcast and conference call with slides tomorrow morning at 8:30 AM EST to discuss these updates. The live and archived webcast will be a

First Quarter 2026 Highlights: Net interest margin of 4.25% Loan growth of 16.2%, annualized 24.7% noninterest income to total revenue1 Net income of $21.6 million, $0.76 per diluted share (adjusted, $23.7 million, $0.84 per diluted share, see "Non-GAAP Financial Measures and Reconciliations" below) Return on average total assets of 1.04% (adjusted, 1.14%, see "Non-GAAP Financial Measures and Reconciliations" below) Return on average stockholders' equity of 7.47% (adjusted, 8.20%, see "Non-GAAP Financial Measures and Reconciliations" below) FirstSun Capital Bancorp ("FirstSun") (NASDAQ:FSUN) reported net income of $21.6 million for the first quarter of 2026 compared to

CHARLESTON, W.Va., April 27, 2026 /PRNewswire/ -- West Virginia American Water is pleased to announce a $500,000 infrastructure upgrade project on 17th Street in Dunbar."We are committed to continued investment in our infrastructure systems across the state," said Scott Wyman, President of West Virginia American Water. "This project will benefit the Dunbar community and customers we serve and allow us to continue providing safe, clean, reliable and affordable water."The project entails replacing 800 feet of aging pipe with 6-inch and 2-inch PVC main and will occur on 17th Street between Fletcher Avenue and Route 25 – Fairlawn Avenue. It is scheduled to be completed by the end of May, and the